Breast cancer is a heterogeneous disease, with side effects, recurrence, and survival varying based on biological characteristics such as receptor status (estrogen receptor [ER], progesterone receptor [PR], and human epidermal growth factor receptor 2 [HER2]—each positive [+] or negative [−]), stage at presentation, and type of treatment received. Yet, clinical guidelines for surveillance are not tailored to account for this variation in risk. As a result, the clinical application of surveillance strategies varies widely following active treatment for breast cancer.
